Table 1:

Demographic information for all individuals included in this study, stratified by TDP-43 diagnosis.

	ALS	FTLD-TDP	LATE-AD+	LATE-AD-
N	141	126	235	69
Age at Onset	59.5 (11.0)	61.0 (9.0)	70.2 (9.0)	68.8 (10.0)
Age at Death	63.7 (10.6)	68.5 (10.0)	80.9 (8.4)	80.9 (8.7)
Disease Duration	4.3 (4.3)	7.3 (4.1)	10.3 (4.3)	11.9 (8.0)
% Female	40.4%	45.2%	62.1%	31.9%
Braak Stage	1.7 (1.7)	2.0 (1.6)	5.8 (0.7)	3.3 (1.4)
% APOE4 Carrier	25.0%	24.6%	63.3%	33.8%
% APOE2 Carrier	12.9%	18.2%	5.2%	8.8%
% Mutation Carrier	19.9%	46.8%	4.2%	5.8%
% Copathology	76.6%	88.9%	42.7%	55.1%
% AD Phenotype	0.0%	12.7%	77.4%	8.7%
% FTDS Phenotype	1.4%	81.7%	9.4%	15.9%
% MND Phenotype	96.5%	0.0%	0.0%	1.4%
% LBD Phenotype	0.7%	0.8%	4.3%	62.3%
% Other Phenotype	1.4%	4.8%	9.0%	11.6%
PMI	12.6 (7.9)	12.8 (7.3)	12.6 (7.1)	11.5 (6.7)

“LATE-AD-” = non-Alzheimer’s individuals with amygdalar but not medullar TDP-43 pathology. “Copathology” = Demonstrates at least one secondary copathology (other than LATE). AD = Alzheimer’s Disease; FTDS = Frontotemporal dementia spectrum; MND = Motor Neuron Disease; LBD = Lewy Body Disease; PMI = Postmortem Interval